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N-methyl-2-pyrrolidone (NMP) is a common solvent
and drug vehicle. We discovered unexpected anti-
neoplastic and immunomodulatory activity of NMP
in a cMYC-driven myeloma model. Coincident to
this, NMP was identified as an acetyllysine mimetic
and candidate bromodomain ligand. Accordingly,
NMP-treated cells demonstrated transcriptional
overlap with BET-bromodomain inhibition, including
downregulation of cMYC and IRF4. NMP’s immuno-
modulatory activity occurred at sub-BET inhibitory
concentrations, and, despite phenotypic similarities
to lenalidomide, its antimyeloma activity was inde-
pendent of the IMiD targets cereblon and Ikaros-1/
3. Thus, low-affinity yet broad-spectrum bromodo-
main inhibition by NMPmediates biologically potent,
cereblon-independent immunomodulation and at
higher doses targets malignant cells directly via
BET antagonism. These data reveal that NMP is a
functional acetyllysine mimetic with pleotropic anti-
myeloma and immunomodulatory activities. Our
studies highlight the potential therapeutic benefits
of NMP, the consequences of current human NMP
exposures, and the need for reassessment of scien-
tific literature where NMP was used as an ‘‘inert’’
drug-delivery vehicle.INTRODUCTION
N-methyl-2-pyrrolidone (NMP) is a common solvent with low
acute toxicity and no genotoxic or carcinogenic effects but is
teratogenic at high exposures (Akesson, 2001; Saillenfait et al.,
2007). Considered inert, NMP is used in applications with human
exposure at high levels (Table S1) (Jouyban et al., 2010). Con-Ccentrations up to 60% v/v (equating to 6 M) are applied in dental
barrier membranes and depot injections (Abouelfadel and
Crawford, 2008; Hou et al., 2004). Transdermal patches contain
up to 10% NMP (Lee et al., 2005). NMP is used to solubilize
hydrophobic drugs, including kinase inhibitors in preclinical
testing, with routine NMP exposures achievingmillimolar plasma
levels in rodents (Carnerup et al., 2005) (Table S2).
Multiple myeloma (MM) is a plasma cell malignancy that
responds to immunomodulatory thalidomide analogs (IMiDs)
(Shortt et al., 2013a). Malignant plasma cells rely on the mutually
permissive effects of IRF4 and cMYC (Delmore et al., 2011;
Shaffer et al., 2008). The IMiDs bind cereblon (CRBN) (Ito et al.,
2010), redirecting its E3-ligase activity toward Ikaros (IKZF)-1
and -3 resulting in IKZF degradation and downregulated cMYC
and IRF4 expression (Lu et al., 2014; Gandhi et al., 2014; Kro¨nke
et al., 2014).
Bromodomain (BRD)-containing proteins ‘‘read’’ acetylly-
sines. BRD and extraterminal domain (BET) family proteins are
recruited to oncogenic superenhancers, augmenting aberrant
cMYC expression (Chapuy et al., 2013). Recently developed
BET inhibitors (e.g., JQ1), possess anti-MM activity due to
cMYC downregulation (Delmore et al., 2011). Thus, although
IMiDs and BET inhibitors have distinct protein targets, cMYC
and IRF4 represent common downstream effectors in MM.
Although testing kinase inhibitors in the Vk*MYC MM model
(Chesi et al., 2012), we noted improved survival in tumor-bearing,
NMP-treated vehicle control mice compared to those treated
with other drug vehicles. Further investigations revealed immu-
nomodulatory activity and cMYC/IRF4 inhibition conveyed by a
potential acetyllysine mimetic pharmacophore. The transcrip-
tome of NMP-treated MM cells was enriched for targets of the
BET inhibition, but also overlapped with that of IMiD treatment.
Despite immunological and transcriptional similarities to IMiDs,
NMP did not alter CRBN, IKZF-1, or IKZF-3 expression, and
NMP demonstrated equal activity against CRBN-deficient and
IMiD-resistant MM cells. Thus, NMP’s activity is mechanistically
distinct from IMiDs and putatively explained by broad-spectrum
BRD antagonism.ell Reports 7, 1009–1019, May 22, 2014 ª2014 The Authors 1009
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Figure 1. NMP Has Activity in Vk*MYC
Myeloma that Is Abrogated in the Absence
of NK and T Cells
(A) Percentage serum paraprotein (M-spike) in
mice bearing aggressive transplanted Vk*MYC
myeloma and treated with daily oral NMP (1 ml/g)
or phosphate buffered saline (PBS).
(B) Kaplan-Meier survival curves for the same
NMP and PBS treatment groups.
(C) Serum from baseline and after 1 month of
treatment was analyzed by ELISA for Igk and Igl
expression.
(D) Change in M-spike from mice bearing indolent
Vk*MYC myeloma and treated with NMP (1 ml/g),
Lenalidomide (LEN)100mg/kgor0.9%saline (SAL)
for 1 month. (*p < 0.05 for reduction from baseline).
(E) Change in serum M-spike in wild-type (WT)
C57BL/6 controls compared to RAG1/ (top
panel) or RAG2xcg/ (lower panel) -immunode-
ficient recipients after 1 week of treatment with
NMP (1 ml/g) or control vehicles (PEG and SAL). All
results are presented as mean ± SEM. *p < 0.05;
NS, not significant.Our data provide insight into the immunological anticancer
mechanisms of BRD inhibitors and mandate that NMP cannot
be considered fit for purpose as an inert drug vehicle. Scientific
data derived using NMP as a vehicle require reanalysis to deter-
mine its contribution to drug responses (Table S2). Current iatro-
genic and occupational NMP exposures require examination
for adverse or therapeutic effects attributable to BRD interac-
tions. Finally, low-affinity, broad-spectrum acetyllysine mimetics
should now be considered for clinical evaluation.
RESULTS
NMP Has Immunomodulatory and Antimyeloma Activity
Vk*MYC MM is an immunocompetent, syngeneic model
that predicts anti-MM clinical efficacy (Chesi et al., 2012).
Although using NMP as a drug vehicle in mice transplanted
with Vk*MYC tumors, we consistently noted antitumor activity
in ‘‘vehicle-only’’ NMP-treated control mice. Responses were
noted in mice transplanted with multiple, independently derived
myelomas demonstrated by delayed paraprotein progression
and improved survival in aggressive clones (Figures 1A and
1B) and sustained regressions in more indolent disease (Fig-1010 Cell Reports 7, 1009–1019, May 22, 2014 ª2014 The Authorsure 1D). Responses were selective for
clonal kappa paraprotein, as residual
polyclonal lambda immunoglobulins
were maintained (Figure 1C). When the
same myeloma was transplanted into
immunodeficient (C57BL/6 RAG1/ or
C57BL/6 RAG2/cg/) hosts, NMP’s
efficacy was attenuated (Figure 1E),
indicating that host lymphocytes were
required for optimal in vivo activity. We
therefore postulated the therapeutic
effects of NMP were mediated by
immunomodulation.NMP was then compared to standard anti-MM therapeutics
in order to elucidate its mechanism of action. Direct cytotoxicity
and glucocorticoid effects were excluded by reference to
published literature (Akesson, 2001; Huang et al., 2011).
Proteasome inhibition was excluded, as NMP treatment did
not increase protein ubiquitination (data not shown). However,
using the gold-standard phenotypic assay of IMiD activity
(Moreira et al., 1993), NMP suppressed tumor necrosis factor
a (TNF-a) release from lipopolysaccharide (LPS)-stimulated
monocytes at similar concentrations to lenalidomide (Figure 2A).
To characterize NMP’s anti-inflammatory effects in vivo,
we challenged non-tumor-bearing mice with LPS after NMP
or lenalidomide prophylaxis (Figures 2B and 2C). A single
‘‘vehicle’’ dose of NMP prevented TNF-a release and
death from endotoxic shock. Lenalidomide only weakly
suppressed TNF-a and failed to improve survival. Because
MM also causes dysregulated inflammatory cytokines, we
assessed the sera of Vk*MYC mice before and after NMP
treatment. Untreated mice bearing Vk*MYC tumors had
elevated TNF-a and interleukin-6 (IL-6) (Figure S1), both of
which were significantly downregulated in response to NMP
(Figure 2D).
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Figure 2. NMP Exhibits Biologically Potent Anti-inflammatory and Immunostimulatory Activity
(A) Human PBMC were LPS stimulated alone or with 10 mM NMP or lenalidomide (LEN) for 18 hr before measurement of TNF-a.
(B) Serum TNF-a 4 hr after LPS challenge in non-tumor-bearing mice prophylaxed with NMP (1 ml/g 3 1 dose) or LEN (100 mg/kg 3 2 doses) or left untreated
(UNT).
(C) Survival curves for the same mice following LPS challenge.
(D) Serum IL-6 and TNF-a from mice bearing indolent Vk*MYC MM after 1 month of treatment with NMP or saline (SAL).
(legend continued on next page)
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In addition to anti-inflammatory activity, the IMiDs costimulate
T cells (Haslett et al., 1998) to augment NK cell cytotoxicity
(Davies et al., 2001). Because NMP’s anti-MM activity was
reduced in T- and NK-deficient mice (Figure 1E), we evaluated
its capacity to costimulate T cells and activate NK cells in vitro.
Like lenalidomide, NMP increased IL-2 release from CD3 stimu-
lated peripheral blood mononuclear cells (PBMCs; Figure 2E)
and augmented NK cell-mediated cytolysis against K562 and
MM targets (Figures 2F and 2G). Pretreatment of MM targets
with NMP also upregulated the DNAM1 and NKG2D ligands
that are required for NK cell-mediated killing (Figure 2H). There-
fore, NMP has anti-inflammatory and immunostimulatory activity
that correlates with attenuation of in vivo anti-MM activity in
immunodeficient hosts.
NMP Is an Acetylated Lysine Mimetic and Bromodomain
Ligand
The results presented in Figure 2 indicated the immunological
effects of NMP overlapped with lenalidomide. However, during
our experiments CRBN was identified as the IMiD binding
protein responsible for anti-MM and immunostimulatory effects
(Ito et al., 2010; Lopez-Girona et al., 2012; Zhu et al., 2011).
Because NMP lacks a glutarimide ring, it is not predicted to
bind CRBN. However, NMP was recently identified as an acetyl-
lysine mimetic with similar affinity for BET-BRDs as their endog-
enous ligands (Figure 3A) (Philpott et al., 2011). Despite weak
biochemical affinity, NMP’s very lowmolecular weight conveyed
ligand efficiency comparable to that of larger rationally devel-
oped compounds such as JQ1 (Hewings et al., 2011; Philpott
et al., 2011). Subsequent characterization of BET-selective
inhibitors revealed anti-inflammatory activity in the context of
LPS challenge, similar to our findings with NMP (Figures 2A
and 2C) (Belkina et al., 2013; Nicodeme et al., 2010). Consistent
with prior studies, JQ1 suppressed TNF-a secretion in response
to LPS challenge to the same extent as NMP (Figure S2). How-
ever, unlike NMP and lenalidomide, low-dose BET inhibition
with JQ1 did not costimulate IL-2 secretion from human PBMCs
(Figure S2).
We therefore evaluated the role of BRD inhibition in NMP
and IMiD responses. Consistent with published data (Philpott
et al., 2011), NMP demonstrated competitive binding with a
range of bromodomain containing proteins when tested in vitro
(Table S3). In contrast to JQ1, NMP bound non-BET targets
including CREBBP and TAF1 (Table S3). Importantly, lenalido-
mide did not demonstrate significant bromodomain interactions
(Table S3).
As cMYC-dysregulation predicts responses to BRD inhibition
(Delmore et al., 2011), we next treated human cMYC-translo-
catedMMcell lines with NMP and JQ1. BET-inhibitory NMP con-
centrations were minimally toxic to human PBMCs (Figure 3B)(E) IL-2 secretion from human PBMCs after stimulation with anti-CD3 in presenc
(F) PBMCs were stimulated with 10 mM NMP or LEN prior to culture with K562 ta
(G) PBMC effectors were treated with 10 mM NMP or left untreated prior to wash
NMP) at a ratio of 50:1 and assessment of cytolysis by chromium release.
(H) Expression of NKG2D (MIC-A, MIC-B, ULBP-1, ULBP-2) and DNAM-1 (CD15
Black line, unstained control; blue line, untreated cells; red line, post drug trea
experiments. *p < 0.05; NS, not significant.
1012 Cell Reports 7, 1009–1019, May 22, 2014 ª2014 The Authorsbut induced cytostasis and apoptosis in cMYC-positive, lenali-
domide-resistant RPMI-8226 myeloma cells (Figure 3C) and
the lenalidomide-sensitive Namalwa Burkitt line (Figure 3D).
NMP responses correlated with rapid downregulation of cMYC
mRNA and protein (Figures 3E and 3F), phenocopying JQ1’s
previously reported effects (Delmore et al., 2011). In contrast,
prolonged lenalidomide exposure was required to downregulate
cMYC in IMiD-sensitive OPM2 MM cells (Figures 3G and 3H).
Thus, NMP and JQ1 share direct anti-MM effects that correlate
with BRD inhibition and acute cMYC suppression. Lenalidomide
lacks BRD-inhibitory activity and downregulates cMYC only after
prolonged treatment.
NMP, JQ1, and Lenalidomide Share Common Molecular
Targets, Including cMYC and IRF4
To identify potentially shared molecular targets of NMP, JQ1,
and lenalidomide, we compared the transcriptional profile of
NMP treatment to published lenalidomide (Zhu et al., 2011)
and JQ1 (Puissant et al., 2013) signatures. NMP differentially
regulated a vast array of genes, further highlighting its previously
unappreciated molecular activity (Figure 4A). Consistent with
data shown in Figure 3, the most downregulated gene at 4 hr
was cMYC. Competitive gene set testing was performed using
CAMERA (Wu and Smyth, 2012), to test for enrichment of lenali-
domide and JQ1 signatures in the RNA sequencing (RNA-seq)
data from NMP-treated cells (Figures 4B and 4C). The profile
of lenalidomide-treated MM cells and a consensus JQ1 signa-
ture were both highly enriched in the NMP-treated cells (Figures
4B and 4C). Direct comparison of JQ1 with lenalidomide also
yielded a highly significant correlation (Figure 4D). To clarify the
specificity of this observation, we also compared with 50 azaciti-
dine, a DNA-methyltransferase inhibitor that does not inhibit
BRDs (Matthews et al., 2013). In contrast to the overlap between
JQ1, NMP, and lenalidomide, 50 azacitidine yielded a distinct
profile with no enrichment for BRD inhibitor or lenalidomide
signatures (Figures 4E and 4F).
We next compared the expression profile of lenalidomide
treatment (Zhu et al., 2011) to the 50 most up- and downregu-
lated genes across three JQ1-treated, cMYC-translocated cell
lines (Delmore et al., 2011). Of these highly JQ1-responsive
genes, 28% (14/50) and 40% (20/50), respectively, were concor-
dant with changes observed with lenalidomide (Figure 4G).
Moreover, these shared genes were concordantly regulated by
NMP, with high statistical significance after 24 hr treatment (Fig-
ure 4H). Notably, cMYC downregulation was common to JQ1,
NMP, and lenalidomide. The MSigDB compute overlaps tool
(http://www.broadinstitute.org/gsea/msigdb/annotate.jsp) was
used to identify known gene sets overlapping this ‘‘JQ1-lenalido-
mide-NMP common’’ signature. The gene sets identified were
enriched for pathways regulated by cMYC and IRF4 (Table S4).e 10 mM NMP, LEN, or DMSO vehicle for 72 hr.
rgets at a 50:1 ratio and assessed for cytolysis by chromium release.
ing and coculture with U266 targets (either untreated or pretreated with 10 mM
5) ligands on U266 MM cells after treatment for 48 hr with 10 mM NMP or LEN.
tment. Results are represented as mean ± SEM of least three independent
AB C D
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(legend on next page)
Cell Reports 7, 1009–1019, May 22, 2014 ª2014 The Authors 1013
IRF4 itself was downregulated by NMP, which we validated on a
second MM cell line (Figures 4I–4J). These data confirm that
NMP is a functional BRD inhibitor and demonstrate that BRD
inhibitors and IMiDs share common molecular targets. Im-
portantly, in the context of robust anti-MM activity, pathways
modulated by cMYC and IRF4 were significantly and coordi-
nately altered.
NMP Has CRBN-Independent Activity in Lenalidomide-
Resistant Multiple Myeloma Cells
Because the thalidomide-binding protein CRBN mediates IMiD
effects, we investigated the role of the CRBN-IKZF1/3 axis in
the anti-MM activity of NMP. We again utilized published data
comparing the expression profile of MM cells following shRNA
CRBN knockdown or lenalidomide treatment (Zhu et al., 2011).
The transcriptional overlap between JQ1, NMP, and lenalido-
mide was virtually entirely mutually exclusive of genes shared
between lenalidomide and CRBN knockdown (Figure 5A). Inter-
estingly, a greater proportion of geneswere shared between JQ1
and lenalidomide (34% concordance) than lenalidomide and
CRBN knockdown itself (10% concordance) (Figure 5A).
Notably, and in contrast to lenalidomide treatment, cMYC was
not represented in the CRBN-knockdown data (of genes with
at least 1 log fold-change reduction). Consistent with these
observations, CAMERA analysis did not show enrichment of
the CRBN-knockdown signature in NMP-treated cells (Fig-
ure 5B). NMP and JQ1 did not downregulate CRBN transcription
at time points corresponding to maximal cMYC suppression
(Figure 5C). Because CRBN has multiple isoforms (Lode´ et al.,
2013), we inspected read mapping of the CRBN locus for evi-
dence of differential isoform expression in RNA-seq data (Fig-
ure S3). Again, there was no evidence of differential CRBN
mRNA splicing in response to NMP treatment. Western blot for
CRBN in OPM2 cells showed multiple bands representing these
putative splice variants. Although a dominant band running
at z45 kDa reduced in response to NMP and JQ1 treatment,
this could be rescued by addition a pan-caspase inhibitor, indi-
cating degradation downstream of apoptosis induction (Fig-
ure 5D). Ikaros-1 and -3 are targets of lenalidomide-bound
CRBN that are ubiquitinylated and degraded in response to
IMiDs (Lu et al., 2014; Gandhi et al., 2014; Kro¨nke et al., 2014).
Unlike lenalidomide, NMP and JQ1 did not affect IKZF-1 or -3
expression (Figure 5E). Together these data indicate that the
transcriptional and immunological similarities between lenalido-
mide and NMP are not explained by convergence on CRBN or
the IKZF transcription factors.Figure 3. NMP Is an Acetyllysine Mimetic Bromodomain Ligand
(A) Chemical structures of acetyllysine, NMP, JQ1, DMSO, and lenalidomide (LEN
glutarimide structure colored blue. IC50 for BRD4 andCREBBP as reported in an a
tabulated below.
(B and C) (B) Percentage Annexin-V/propidium iodide (PI) positive PBMCs or (C
(10 mM), or JQ1 (0.5 mM).
(D) Cell-cycle analysis (nuclear DNA content [PI] staining) for Namalwa Burkitt ce
(E and F) (E) RPMI-8226 and (F) OPM2 myeloma cells were treated with NMP 10
(upper panel) or 24 hr prior to western blotting (lower panel) for cMYC expressio
(G) RPMI-8226 and OPM2 cells were treated with LEN 10 mM or DMSO for 48 hr
(H) OPM2 cells were treated with LEN 10 mM (upper blot) or DMSO control (lower
All results are mean ± SEM of least three independent experiments; *p < 0.05.
1014 Cell Reports 7, 1009–1019, May 22, 2014 ª2014 The AuthorsSecondary lenalidomide resistance is associated with muta-
tion and/or downregulated expression of CRBN (Zhu et al.,
2011). We therefore investigated the potential CRBN-indepen-
dent activity of NMP in the setting of acquired IMiD resistance
due to CRBN knockdown or prolonged lenalidomide exposure
(Figures 5F–5I). The phenotype of acquired lenalidomide resis-
tance was validated by demonstrating attenuated reductions in
IKZF-1 and -3 after lenalidomide exposure in CRBN knockdown
or chronically lenalidomide-treated cells (Figure S4). Consistent
with CRBN-independent activity, NMP induced similar growth
arrest in MM cells with either CRBN-knockdown or acquired
IMiD resistance (Figures 5G–5I).
DISCUSSION
MM is an incurable disease that initially responds to IMiDs, pro-
teasome inhibitors, and emerging epigenetic therapies (Shortt
et al., 2013a). Here, we report the serendipitous discovery that
NMP, a drug-vehicle previously considered biologically inert,
has immunomodulatory and anti-MM activity. A key discovery
of our work was that NMP’s biological effects overlapped with
both BET inhibition and the IMiDs. At a molecular level, NMP
functions as a nonselective BRD inhibitor, whereas lenalidomide
does not bind BRDs. However, MM cells treated with NMP, JQ1,
or lenalidomide shared highly convergent gene expression
signatures, indicating that these chemically diverse agents may
mediate antitumor responses through common mechanisms.
However, clear mechanistic distinctions set lenalidomide
apart from NMP and JQ1. Lenalidomide acts at a post-
translational level, binding CRBN to induce IKZF1/3 degradation
upstream of cMYC and IRF4. BRD inhibition (by NMP or JQ1)
directly antagonizes cMYC and IRF4 transcription, independent
of CRBN or IKZF1/3. Accordingly, NMP’s activity was preserved
in CRBN-deficient and lenalidomide-resistant MM cells. This
indicates that BRD inhibitors are likely to have utility in MM
with secondary IMiD resistance due to perturbations of the
CRBN-IKZF1/3 axis.
The low mM NMP concentrations required to antagonize BET
proteins coincide with direct cytostatic effects on cMYC-translo-
cated cells. In this regard, NMP is a biochemically weak BET
inhibitor compared to JQ1. However, the routine use of 10%
NMP (1 M or 1 g/kg) to deliver kinase inhibitors to rodents readily
achieves mM plasma concentrations. For example, a 500 mg/kg
NMP dose results in median peak plasma concentrations of
7 mM in rats (Carnerup et al., 2005). Therefore, systemic BET-
inhibitory NMP concentrations must be assumed in most) with bromodomain interacting moiety highlighted in red and cereblon binding
lpha-screen by Philpott et al. (2011) or extrapolated fromBromoMax screen are
) RPMI-8226 myeloma cells after 48 hr treatment with NMP (1–20 mM), LEN
lls after 48 hr treatment with NMP (1–20 mM), LEN (10 mM), or JQ1 (0.5 mM).
mM, LEN 10 mM, JQ1 0.5 mM, or DMSO vehicle for 2 hr prior to real-time PCR
n.
before quantitation of cMYC by real-time PCR.
blot) and harvested at the indicated time points and western blotting for cMYC.
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Figure 4. NMP Shares Overlapping Molecular Targets with Lenalidomide and JQ1
(A) The number of differentially regulated genes in JJN3 MM cells treated with 10 mM NMP. Red and blue bars indicate up and downregulated genes,
respectively.
(B) Gene set testing represented as barcode graph showing rankings of the ‘‘Zhu’’ lenalidomide (LEN) signature in the expression data from NMP-treated JJN3
cells.
(legend continued on next page)
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preclinical rodent studies. Given our data, all studies using NMP
to deliver small molecules (Table S2) need to be scrutinized and
may require reinterpretation.
NMP’s immunomodulatory effects were evident at 10 mM and
approximated that of the clinical lead IMiD, lenalidomide. This
activity at concentrations 1,000 3 lower than its biochemical
IC50 for BET-BRDs requires further explanation, particularly
because BET inhibition by JQ1 was not immunostimulatory.
The BET family represents a minor proportion (4/41) of human
BRD proteins that NMP potentially interacts with (Filippakopou-
los et al., 2010). Indeed, many non-BET BRD targets are ‘‘less
druggable’’ than BET proteins due to a shallow BRD pocket
that may still be occupied by NMP (Vidler et al., 2012). NMP’s
very low molecular weight may also contribute to greater intra-
cellular bioavailability and activity than would be predicted on
the basis of binding affinities identified through biochemical
assays. For example, the reported ligand efficiency of NMP for
CREBBP is 0.53, this being superior to that of JQ1 for BRD4
(0.32) despite IC50s of 2.4 mM and 77 nM, respectively (Hewings
et al., 2011).
Although the relative affinity of NMP for the complete BRD-
protein family is yet to be mapped, our limited screen identified
selectivity for CREBBP and TAF1 over BET proteins, and others
have reported the binding of NMP to SMARCA4 and PB1 (Fili-
ppakopoulos et al., 2012). PB1, TAF1, and SMARCA4 are all
considered to have difficult ‘‘druggability’’ compared to BET
proteins (Vidler et al., 2012) and may represent important immu-
nomodulatory NMP targets. Indeed, SMARCA4 has demon-
strated roles in inflammation (Ramirez-Carrozzi et al., 2006)
and regulatory T cell function (Chaiyachati et al., 2013). The
possible effects of NMP-mediated inhibition of non-BET-BRD
proteins remain the focus of future studies.
The human significance of NMP’s biological activity is immedi-
ate. Iatrogenic and occupational NMP exposures are common
and occur at high concentrations. Because neat NMP is 10 M,
concentrations proximal to depot injections and dental barrier
membranes will extend into the molar (and BET inhibitory)
concentration range. We also provide data indicating a one-
million-fold dilution of NMP has immunomodulatory effects
with similarities to lenalidomide. Single-dose transdermal deliv-
ery of 300mgNMP to healthy volunteers resulted in peak plasma
concentrations up to 44 mM (Akesson et al., 2004). Therefore,
systemic immunomodulation by NMP with existing common
human exposures is plausible.
NMP’s capacity to combine CRBN-independent immuno-
modulatory activity with broad-spectrum BRD antagonism
provides a unique therapeutic modality with predicted activity(C) Gene rankings of the consensus ‘‘Puissant’’ JQ1 signature in the expression
(D) Rankings of the ‘‘Puissant’’ JQ1 signature in the ‘‘Zhu’’ LEN expression data.
(E and F) (E) Gene rankings of the ‘Zhu’ LEN signature and the (F) ‘‘Puissant’’ JQ
(G) Venn diagrams demonstrating overlap between the 50 most up- and downreg
change in expression in OPM2 myeloma cells in response to LEN (‘‘Zhu’’). Uppe
(H) Heatmap showing expression of genes common to JQ1 ‘‘Delmore’’ and LEN ‘‘Z
gene (*genes with FDR q < 0.05).
(I) qPCR for IRF4 expression in OPM2 cells treated for 2–6 hr with NMP (10 mM)
(J) Western blot of IRF4 expression in OPM2 cells treated for 24 hr with NMP (10
All data are representative of at least three independent experiments. #p < 0.05; F
correction; p values for gene set testing are from CAMERA and indicate the sign
1016 Cell Reports 7, 1009–1019, May 22, 2014 ª2014 The Authorsin the setting of IMiD-resistant MM. Additional therapeutic
benefit may already be evident, because NMP (a potential
component of orthopedic cement) was reported to augment
bone hardening through activation of BMP signaling (Miguel
et al., 2009). Because osteoporosis causes significant morbidity
in MM, an agent that conveys dual antineoplastic and pro-oste-
oblastic activity is highly desirable. Potent BET-selective inhibi-
tors have now entered clinical development, but experience
with these agents is limited. In contrast, good manufacturing
practice grade NMP is inexpensive, readily available, nontoxic,
and already tested in human volunteers. Repurposing NMP as
a clinical therapeutic is imminently feasible and will be pursued
in an Australian phase I study in 2014.
EXPERIMENTAL PROCEDURES
In Vitro Cell Culture, Reagents, and Assays
Cell lines were all from ATCC except JJN3s (a gift from Prof. Andrew Spencer)
and lenalidomide-resistant U266 cells (a gift from Prof. Keith Stewart); these
were cultured in RPMI-1640 with 10% fetal calf serum and penicillin/strepto-
mycin. Apoptosis and cell-cycle analyses were performed as previously
described (Shortt et al., 2013b).
NMP was purchased from Sigma-Aldrich. Lenalidomide and 5-azacitidine
were provided by Celgene. JQ1 was provided by Prof. James Bradner. qVD
was purchased from Calbiochem.
Chromium release assays were performed using PBMCs as previously
described (Hsu et al., 2011). TNF-a suppression assays utilized LPS-stimu-
lated human CD14+monocytes in the presence of drug or media for 18 hr prior
to supernatant collection. Costimulation assays were performed on anti-CD3
stimulated PBMCs, alone or in the presence of drugs for 72 hr prior to super-
natant collection. Cytokines levels were measured by bead array (Luminex).
Bromodomain competition assays were performed by BROMOscan
(Discoverex). Western blots were performed according to standard techniques
(Shortt et al., 2013b). Primary antibodies were cMYC (Cell Signaling Technol-
ogy), IRF4 (Santa Cruz Biotechnology), CRBN (Proteintech), IKZF1 (Santa
Cruz), IKZF3 (Abcam), a-tubulin (Merck), and b-Actin (Sigma-Aldrich). Anti-
bodies for NKG2D and DNAM-1 ligands were from R&D Systems.
Quantitative real-time PCR was undertaken using SYBR green nucleic acid
stain (Invitrogen) and the following primers:CRBN F: caccctcaagaagtcagtatgg
R: aaactgtgcttccctttcct; cMYC F: ggacgacgagaccttcatcaa R: ccagcttctctga
gacgagctt; IRF4 F: tccccacagagccaagcataaggt R: acgaggatttcccggtagta;
normalized to L32: F: ttcctggtccacaacgtcaag R: ttgtgagcgatctcggcac in an
ABI7900HT (Applied Biosystems). shCRBN and shNT lentiviral constructs
were a gift from Prof. Keith Stewart (Zhu et al., 2011).
RNA Sequencing and Bioinformatics
Myeloma cells were treated for 4 or 24 hr prior to RNA extraction in three inde-
pendent experiments. Paired-end reads (50 bp) were generated on an Illumina
HiSeq and quality checked by FastQC and then mapped to the human refer-
ence genome (GRCh37) using Tophat2 v2.0.8b (PMID: 23618408) with
maximum number of multiple hits set to 1 and first mapping to the reference
transcriptome (Ensembl v69). Counts per gene were obtained using HTSeqdata from NMP-treated JJN3 cells.
1 signature in expression data from 5-azacitidine (2.5 mM) -treated JJN3 cells.
ulated genes in JQ1-treated MM cell lines (‘‘Delmore’’) and genes with >2-fold
r panel, upregulated (UP); lower panel, downregulated (DN) genes.
hu’’ in NMP-treated versus untreated (UNT) JJN3myeloma cells normalized by
, JQ1 (0.5 mM), or vehicle (DMSO).
mM), JQ1 (0.5 mM), or vehicle (DMSO).
C, fold change; FDR, q value, statistical significance after false discovery rate
ificance of enrichment.
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Figure 5. NMP Has CRBN-Independent Activity versus Myeloma with Acquired Lenalidomide Resistance
(A) Venn diagrams demonstrating overlap between 50 most differentially regulated genes in JQ1-treated myeloma cell lines (‘‘Delmore JQ1’’) and genes with >2-
fold change (FC) in expression following 48–72 hr of CRBN knockdown (‘‘Zhu CRBN KD’’) or 48 hr lenalidomide treatment (‘‘Zhu LEN’’). Left panel, upregulated
(UP) genes; right panel, downregulated (DN) genes.
(B and C) (B) Barcode plot showing the rankings of genes with >2 FC in expression following CRBN knockdown (‘‘Zhu CRBN KD’’) in expression data from NMP-
treated (10 mM, 24 hr) JJN3 myeloma cells (C) qPCR for CRBN expression in OPM2myeloma cells treated for 2–6 hr with NMP (10 mM), JQ1 (0.5 mM), or DMSO.
(D) Western blot of CRBN in OPM2 myeloma cells treated for 24 hr with NMP (10 mM), JQ1 (0.5 mM), or DMSO with or without the pan-caspase inhibitor, qVD.
(legend continued on next page)
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v0.5.3p9 with mode intersection nonempty (http://www.huber.embl.de/users/
anders/HTSeq/doc/overview.html). The limma-voom method was used to
identify differentially expressed genes between drug treatment and control
using a false discovery rate (FDR) threshold of 0.05 (http://www.statsci.org/
smyth/pubs/VoomTechReport.pdf).
Gene set testing was performed using CAMERA (Wu and Smyth, 2012) and
the MSigDB v3.1 C2 curated gene set collection (Subramanian et al., 2005).
The Zhu expression data were downloaded from Gene Expression Omnibus
(GEO) accession number GSE31421. These are expression files for lenalido-
mide-treated or CRBN shRNA-infected OPM2 cells. The cel files were loaded
into R and normalized with gcrma. Because the data contained no replication,
a t-statistic could not be generated to calculate p values, so fold-change cut-
offs were used to construct gene signatures. For CRBN knockdown, we
selected genes exhibiting a 2-fold change at 48 and 72 hr. For lenalidomide
treatment, we used minimum fold change of 3 at 48 hr and 4 at 72 hr to ensure
sufficient gene numbers for interrogation of other data sets.
In Vivo Experiments
Mouse experiments were performed in accordance with Peter Mac Animal
Experimental Ethics Committee guidelines. All strains were on a C57BL/6
background and purchased from the Walter & Eliza Hall Institute (Parkville,
Australia) or bred in-house. In vivo studies were performed on mice bearing
transplanted Vk*MYC myeloma as previously described (Chesi et al., 2012).
To prevent adoptive transfer of immune cells with grafts into immunodeficient
mice, we transplanted fluorescence-activated cell-sorted CD138+ cells. Prior
to treatment, the onset of transplanted disease was confirmed by serum
protein electrophoresis. For quantitative immunoglobulin estimates, serum
was analyzed by ELISA using Igl or IgK capture antibodies (Southern
Biotech).
Mice were gavaged with NMP diluted in PEG300 (Sigma-Aldrich) according
to standard practice for drug administration using NMP/PEG as a vehicle. JQ1
was administered by intraperitoneal injection in 10% DMSO/9%HPBCD/81%
sterile water. Lenalidomide was gavaged in 0.9% saline suspension. Mice
were culled with the development of overt myeloma, including hind-limb paral-
ysis and disseminated extramedullary disease.
For LPS challenges, mice were administered LPS (E. coli 0127:B8, gamma-
irradiated; Sigma) 1 mg/30 g mouse weight by i.p. injection, and serum was
obtained 4 hr after injection. For cytokine assessment in myeloma-bearing
mice, serum was collected 4 hr after the last dose of treatment.
Statistical Analysis
One-way ANOVA was used to compare means of multiple groups; t tests
and Mann-Whitney tests were used to compare the means of two groups.
Statistical comparisons and log-rank (Mantel-Cox) survival analyses were
calculated using GraphPad Prism version 5.0b at the a = 0.05 level of
significance.
ACCESSION NUMBERS
The GEO accession number for the RNA sequencing data reported in this
paper is GSE56623.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and four tables and can
be found with this article online at http://dx.doi.org/10.1016/j.celrep.2014.
04.008.(E) Western blot of IKZF-1 and -3 expression in U266 and OPM2 MM cells treate
(F) Cell-cycle analysis of OPM2 cells expressing shCRBN or shNT control after 4
(G) Cell-cycle analysis of OPM2 cells expressing shCRBN or shNT control after 4
(H) Cell-cycle analysis of parental and LEN-resistant U266 myeloma cells after 4
(I) Cell-cycle analysis of parental and LEN-resistant U266 myeloma cells after 48
All data are representative of at least three independent experiments. p values for
#p < 0.05 for a reduction in S phase.
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